Tubulis GmbH

Reimagining ADCs.

Founded 2019 Germany

Germany 73 employees Acquired Total: $3.66B Biotechnology, Health Care +3

General Information

Company Name Tubulis GmbH

Founded Year 2019

Location

Germany

Employees 73

Industries Biotechnology, Health Care, Health and Wellness +2

Funding Stage Acquired

Business Model B2B, B2D

Revenue Model Licensing, Project Based, Performance Based

Social

BounceWatch is an independent company data service, not affiliated with Tubulis GmbH. To contact Tubulis GmbH, visit tubulis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Tubulis GmbH compare?

A PDF of Tubulis GmbH and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Tubulis GmbH soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

From the desk

Is Tubulis GmbH on your competitive set?

Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.

Book a 7-day Readout

Discover More

Germany Market

Market Signals All Companies

Biotechnology

Industry Signals All Companies in Germany

Tubulis GmbH Alternatives

All Signals Trend Reports

About Tubulis GmbH

Tubulis GmbH, with its slogan "Reimagining ADCs.", represents a significant stride in the biotechnology space. Founded in 2019, the company quickly positioned itself at the intersection of Biotechnology, Health Care, Health and Wellness, Life Sciences, and Pharmaceutical sectors. Its headquarter is based in Germany, emphasizing its European roots and outreach.

Now integrated into Gilead Sciences, a renowned biopharmaceutical firm known for over three decades of medical innovation, Tubulis stands at the forefront of advancing healthcare solutions globally. This latest integration supports Gilead's ongoing commitment to enhance medical capabilities and accessible healthcare.

The acquisition was completed on April 1, 2026, with a substantial investment of $3.15B by Gilead Sciences, marking a pivotal point in the company’s journey. This acquisition not only underscores Tubulis' innovative potential but also highlights Gilead’s strategic efforts to expand its footprint in the ADCs market.

Business keywords: Antibody Drug Conjugates, Targeted Therapy, Drug Development, Chemotherapy Alternatives, Cancer Treatment, Protein-Drug Conjugates, Disease-Specific Biology, Pharmaceuticals, Chronic Disorder Treatment, Innovative Technology, Oncology

Services & Products

ADC Development

Clinical Research

Biophysical Property Analysis

Target Customers

Pharmaceutical Companies Medical Researchers Oncologists Cancer Patients

Funding Rounds & Investors (11)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Acquisition	$3.15B	1	Gilead Sciences	01 Apr 2026
Series C	€308.00M	13	Bayern Kapital, Seventure Partners +11	01 Oct 2025
Late VC	Undisclosed	18	Bayern Kapital, EQT Ventures +16	01 Jun 2025
Series B	€128.00M	13	Bayern Kapital, Seventure Partners +11	01 Mar 2024
Support Program	Undisclosed	1	Falling Walls Foundation	01 Nov 2022
Series B	€60.00M	9	Bayern Kapital, Seventure Partners +7	01 May 2022
Series A	€10.70M	6	Bayern Kapital, Seventure Partners +4	01 Jul 2020
Spinout	Undisclosed	3	University Ventures, Ology Capital +1	01 Jan 2019
Support Program	Undisclosed	1	EIT Health	01 Jan 2018
Grant	€1.30M	-		01 Jul 2017

View All 11 Funding Rounds

Latest News

View All

Healthtech: 10 companies that raised the most in 2025

Tech May 07, 2026

From industrial depth to strategic growth: the German tech ecosystem

Tech Feb 12, 2026

French BioTech company ErVimmune raises €17 million to tackle hard-to-treat cancers

Eu-startups Jan 21, 2026

HTGF: Where public mandate meets venture discipline

Tech Jan 15, 2026

UK’s Nuclera brings Series C funding to €74 million following €10 million extension for its eProtein... — Eu-startups

UK’s Nuclera brings Series C funding to €74 million following €10 million extension for its eProtein Discovery system

Eu-startups Jan 13, 2026

London’s Engitix secures €21 million extension to advance ECM-targeted cancer and fibrosis therapies

Eu-startups Jan 08, 2026

Tubulis GmbH Alternatives & Competitors

View All Alternatives

Tubulis GmbH vs

Arcellx United States

Arcellx is a clinical-stage biotechnology company based in Redwood City, California

Acquired

121 employees

Biopharma, Biotechnology

Compare Tubulis GmbH vs Arcellx

Tubulis GmbH vs

NBE-Therapeutics AG Switzerland

Next generation antibody drug conjugates

Series C

48 employees

Biotechnology, Health Care

Compare Tubulis GmbH vs NBE-Therapeutics AG

Tubulis GmbH vs

Pyxis Oncology United States

Charting a course to therapeutics for difficult-to-treat cancer.

68 employees

Biotechnology, Health Care

View all alternatives

FAQ About Tubulis GmbH

Reimagining ADCs.

Tubulis GmbH was founded in 2019.

Tubulis GmbH is headquartered in Germany.

Tubulis GmbH operates in Biotechnology, Health Care, Health and Wellness, Life Sciences and Pharmaceutical. Its work centres on Antibody Drug Conjugates, Targeted Therapy, Drug Development and Chemotherapy Alternatives. Its customers include Pharmaceutical Companies, Medical Researchers and Oncologists.

Tubulis GmbH has a B2B and B2D business model. Its revenue comes from Licensing, Project Based and Performance Based.

Tubulis GmbH has approximately 73 employees.

Tubulis GmbH has completed 11 funding rounds, raising a total of $3.66B. The latest funding stage is Acquired.

Tubulis GmbH offers: ADC Development, Clinical Research, Biophysical Property Analysis.

Top alternatives and competitors to Tubulis GmbH include Arcellx, NBE-Therapeutics AG, Pyxis Oncology, Abdera Therapeutics, Myricx Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Tubulis GmbH and Arcellx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Tubulis GmbH, https://bouncewatch.com/company/tubulis, updated 26 September 2026. When citing, please name BounceWatch and link this page.